Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

CAPIVASERTIB for Hormone-dependent prostate cancer: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 7 adverse event reports in the FDA FAERS database where CAPIVASERTIB was used for Hormone-dependent prostate cancer.

Most Reported Side Effects for CAPIVASERTIB

Side Effect Reports % Deaths Hosp.
Diarrhoea 278 16.4% 11 88
Rash 253 15.0% 3 64
Death 228 13.5% 221 10
Hyperglycaemia 152 9.0% 16 71
Nausea 96 5.7% 5 34
Vomiting 81 4.8% 7 34
Blood glucose increased 70 4.1% 5 31
Fatigue 67 4.0% 5 18
Malignant neoplasm progression 62 3.7% 11 13
Disease progression 61 3.6% 1 2
Pyrexia 55 3.3% 1 31
Diabetic ketoacidosis 52 3.1% 21 39
Decreased appetite 46 2.7% 7 20
Dehydration 45 2.7% 5 29
Urinary tract infection 43 2.5% 5 16

Other Indications for CAPIVASERTIB

Breast cancer female (395) Breast cancer (287) Breast cancer metastatic (182) Product used for unknown indication (50) Breast cancer recurrent (36) Neoplasm malignant (28) Her2 negative breast cancer (12) Breast cancer stage iv (11) Her2 positive breast cancer (11) Hormone receptor positive breast cancer (11)

Other Drugs Used for Hormone-dependent prostate cancer

APALUTAMIDE (533) DAROLUTAMIDE (294) ENZALUTAMIDE (289) ABIRATERONE (236) DEGARELIX (187) LEUPROLIDE (181) DOCETAXEL (90) PREDNISONE (47) DOCETAXEL\DOCETAXEL ANHYDROUS (42) GALLIUM GA-OZETOTIDE (41)

Related Pages

CAPIVASERTIB Full Profile All Hormone-dependent prostate cancer Drugs CAPIVASERTIB Demographics CAPIVASERTIB Timeline